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Abstract
Objective: Laboratory studies suggest elevated blood pressure after resuscitation from cardiac 
arrest may be protective; however, clinical data are limited. We sought to test the hypothesis that 
elevated post-resuscitation mean arterial blood pressure (MAP) is associated with neurological 
outcome.
Design: Pre-planned analysis of a prospective cohort study.
Setting: Six academic hospitals in the United States.
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Patients: Adult, non-traumatic cardiac arrest patients treated with targeted temperature 
management after return of spontaneous circulation (ROSC).
Interventions: MAP was measured non-invasively after ROSC and every hour during the initial 
six hours after ROSC.
Measures and Main Results: We calculated the mean MAP and a priori dichotomized 
subjects into two groups: mean MAP 70–90 and > 90 mmHg. The primary outcome was good 
neurological function, defined as a modified Rankin Scale (mRS) ≤ 3. The mRS was prospectively 
determined at hospital discharge. Of the 269 patients included, 159 (59%) had a mean MAP > 90 
mmHg. Good neurological function at hospital discharge occurred in 30% of patients in the entire 
cohort, and was significantly higher in patients with a mean MAP > 90 mmHg (42%) as compared 
to MAP 70–90 mmHg (15%) [absolute risk difference 27% (95% CI 17%−37%)]. In a 
multivariable Poisson regression model adjusting for potential confounders, mean MAP > 90 
mmHg was associated with good neurological function, adjusted relative risk 2.46 (95% CI 2.09–
2.88). Over ascending ranges of mean MAP, there was a dose-response increase in probability of 
good neurological outcome, with mean MAP > 110 mmHg having the strongest association, 
adjusted relative risk 2.97 (95% CI 1.86 – 4.76).
Conclusions: Elevated blood pressure during the initial six hours after resuscitation from 
cardiac arrest was independently associated with good neurological function at hospital discharge. 
Further investigation is warranted to determine if targeting an elevated MAP would improve 
neurologic outcome after cardiac arrest.
Keywords
blood pressure; cardiac arrest; heart arrest; resuscitation
Introduction
Cardiac arrest occurs in over 400,000 people each year in the United States alone.(1) Even 
among those who attain return of spontaneous circulation (ROSC) after cardiac arrest, in-
hospital mortality remains over 50%, with a large proportion of survivors experiencing 
permanent and severe neurological disability.(2) After ROSC there is ongoing cerebral 
injury secondary to oxidant damage.(3, 4) Thus, finding new approaches to attenuate brain 
injury after resuscitation is a high priority for resuscitation science.
Brain injury secondary to cardiac arrest can result in disruption of normal cerebrovascular 
autoregulation.(5, 6) As a result, cerebral blood flow may become directly related to cerebral 
perfusion pressure.(6) Thus, an elevated mean arterial blood pressure (MAP) after 
resuscitation from cardiac arrest could improve cerebral blood flow through increased 
cerebral perfusion pressure, potentially attenuating ongoing cerebral injury. Current post-
cardiac arrest guidelines recommend avoiding and immediately correcting post-resuscitation 
hypotension.(7, 8) However, there is currently insufficient evidence to recommend a specific 
blood pressure target. Our group previously published a single center prospective cohort 
study demonstrating an association between post-resuscitation MAP < 70 mmHg and poor 
neurological outcome at hospital discharge.(9) However, secondary to sample size 
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limitations we were unable to adequately test whether higher MAPs were associated with 
improved neurological outcome.
In this multi-center cohort study, our main objective was to test the association between 
elevated post-resuscitation MAP and neurological outcome among adult patients 
successfully resuscitated from cardiac arrest.
Methods
Setting
We performed a pre-planned analysis of a prospective cohort study across six hospitals in 
the United States. We prospectively compiled and maintained an Utstein style cardiac arrest 
registry.(10, 11) The Institutional Review Board at each participating institution approved 
this study. This study is reported in accordance with the Strengthening the Reporting of 
Observational Studies in Epidemiology (STROBE) Statement.(12)
Participants
Adult post-cardiac arrest patients who were comatose after ROSC between July 2013 and 
March 2017 were included. The inclusion criteria were: 1) age ≥ 18 years; 2) cardiac arrest, 
defined as a documented absence of pulse and the initiation of cardiopulmonary 
resuscitation (CPR); 3) ROSC > 20 min; 4) unresponsive (i.e. Glasgow Coma Score motor 
less than 6) and mechanical ventilation after ROSC; and 5) clinician intent to perform 
targeted temperature management. We included patients with both in- and out-of-hospital 
cardiac arrest in order to allow for a pragmatic study from which results could be broadly 
applicable to as many cardiac arrest patients as possible. We excluded subjects with 
presumed etiology of arrest secondary to trauma, hemorrhage or sepsis; residents of a 
nursing home or other long-term care facility; pregnancy; prisoners; and known lack of 
commitment to aggressive support by next of kin. We excluded patients with persistent 
hypotension during the initial six hours after ROSC (defined as mean post-resuscitation 
MAP < 70 mmHg).(9) We excluded these patients on the grounds that it has already been 
demonstrated that hypotension is associated with worse outcomes.(2, 9, 13, 14) Excluding 
these patients would permit us to focus the analysis on the association between elevations in 
MAP and neurological outcome.
Data Collection
As part of our research protocol we measured MAP immediately after ROSC and hourly 
thereafter using a noninvasive blood pressure cuff for the first six hours after ROSC. We 
calculated the mean MAP over the initial six hours after ROSC. We chose the initial six 
hours as our time frame as it has previously been demonstrated to be the most critical time 
period for hemodynamic optimization after cardiac arrest.(15) We prospectively captured all 
the components of the Sequential Organ Failure Assessment (SOFA) score (i.e. respiratory, 
coagulation, hepatic, renal, cardiovascular, and neurological) during the first six hours after 
ROSC to assess severity of illness.(16) For calculation of the total SOFA score, we excluded 
the neurological component as described previously,(16–18) as well as the cardiovascular 
component given collinearity with MAP. We prospectively captured vasopressor 
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administration during the first six hours after ROSC and used the SOFA cardiovascular score 
to quantify vasopressor dosing. We abstracted clinical data from the medical record into 
Research Electronic Data Capture (REDCap, Vanderbilt University, TN), a secure, internet-
based application designed to support data capture for research studies(19) and exported into 
Stata/SE 14.1 for Mac, StataCorp LP (College Station, TX, USA).
Outcome measures
The primary outcome was good neurological function at hospital discharge, a priori defined 
as a modified Rankin Scale (mRS) ≤ 3.(20, 21) The mRS was prospectively determined as 
part of our research protocol for each patient at the time of hospital discharge. All raters 
were trained and certified in mRS assessment(22) and used a structured questionnaire and 
interview, which have been shown to produce strong interobserver reliability.(23, 24) 
Secondary outcomes were survival to hospital discharge and good early neurological 
response, defined a priori as a Full Outline of UnResponsiveness (FOUR) score > 6 at 72 
hours after ROSC, based on previous literature.(25, 26)
Data Analysis
We began the analysis with descriptive statistics. We displayed categorical data as counts 
and proportions, and continuous data as mean values and standard deviation (SD) or median 
values and interquartile range (IQR), based on distribution of data. Continuous variables 
were compared using student t-test or Wilcoxon rank-sum test, based on the distribution of 
the data and categorical variables were compared using the chi-square test
For our primary analysis we a priori grouped subjects into two categories: mean MAP 70–90 
and > 90 mmHg, based on previous literature.(15) For the primary outcome, we calculated 
relative risks (RR) using multivariable Poisson regression.(27) We entered candidate 
variables that were previously demonstrated to be strong predictors of poor outcome in post-
cardiac arrest patients into the model (see Supplemental Methods for full description of the 
model). The same analyses were performed for the secondary outcomes.
For the primary outcome we performed multiple pre-planned subgroup analyses. We also 
tested if the dose of vasopressor administration modified the association between mean 
MAP and neurological outcome, as well as tested for a dose response between incremental 
increases in mean MAP and neurological outcome (detailed description of sensitivity 
analyses is discussed in Supplemental Methods). Finally, we performed two post-hoc 
sensitivity analyses: (1) we tested the association between the duration of exposure to MAP 
> 90 mmHg and neurological outcome and (2) we tested the primary analysis among only 
patients who survived to hospital discharge. All models used robust standard error and 
allowed for intragroup correlations at the institution (i.e. site of enrollment) level.
Results
Our prospective cohort consisted of 280 subjects (study flow diagram previous published).
(28) Eleven (4%) subjects were excluded for a mean MAP < 70 mmHg leaving 269 subjects 
in the final cohort. The mean (SD) mean MAP was 95 (15) mmHg for the entire cohort, and 
101 (14) and 93 (15) mmHg for subjects with and without good neurological outcome at 
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hospital discharge respectively (p-value < 0.001 using student t-test). One hundred fifty-nine 
(59%) subjects had a mean MAP > 90 mmHg during the initial six hours after ROSC.
Table 1 displays baseline data for all subjects in the cohort, as well as subjects with a mean 
MAP 70–90 and > 90 mmHg. We found that patients with a mean MAP 70–90 mmHg had a 
longer median (IQR) duration of CPR compared to those with a mean MAP > 90 mmHg [17 
(8–28) vs. 10 (6–20) min]. Four subjects (1%) had an unknown duration of CPR. 
Supplemental Table 1 displays post-cardiac arrest data for all subjects. All subjects were 
mechanically ventilated after ROSC and received target temperature management. Several 
variables were statistically different at p < 0.10 when comparing mean MAP 70–90 mmHg 
and > 90 mmHg groups: vasopressor administration, Charlson co-morbidity index, and pre-
existing congestive heart failure and malignancy.
Eighty-two (30%) subjects were found to have the primary outcome of good neurological 
function at hospital discharge among the entire cohort. Among subjects with a mean MAP 
70–90 mmHg, good neurological outcome was observed for 15% compared to 42% among 
those with a mean MAP > 90 [absolute risk difference 27% (95% CI 17% - 37%), p < 
0.001]. The proportion of subjects with each mRS score stratified by mean MAP is 
displayed in Figure 1.
In total, 218 subjects survived to 72 hours, and 81 (74%) vs. 137 (86%) survived to 72 hours 
among patients with a mean MAP 70–90 and > 90 mmHg respectively (p = 0.01). Among 
the entire cohort that survived to 72 hours the median (IQR) FOUR score was 8 (3–13). 
Patients with a mean MAP > 90 mmHg had a higher median (IQR) FOUR score compared 
to patients with a MAP 70–90, [11 (5–13) vs. 6 (2–11), p < 0.001 using Wilcoxon rank-sum 
test], as well as a higher proportion of good early neurological response [66% vs. 49%, 
absolute risk difference 17% (95% CI 4% - 30%), p = 0.013
One hundred and twenty-two subjects survived to hospital discharge. Compared to a mean 
MAP 70–90 mmHg, a MAP > 90 mmHg was associated with increased survival to hospital 
discharge [28% vs. 57%, absolute risk difference 29% (95% CI 18% - 40%), p < 0.001]. 
Survival to hospital discharge among patients with and without good early neurological 
response was 80% vs. 18% respectively, absolute risk difference 62% (95% CI 51% - 72%), 
p < 0.001]. Of note a higher proportion of patients with a mean MAP 70–90 mmHg had 
withdraw of life sustaining therapy during hospitalization compared to MAP > 90 mmHg 
[58% vs. 35% respectively, p < 0.001].
Table 2 displays the results of the multivariable Poisson regression models for the primary 
and secondary outcomes. After adjusting for potential confounders, a mean MAP > 90 
mmHg was an independent predictor of good neurological function at hospital discharge, 
relative risk 2.46 (95% CI 2.09 – 2.88), p < 0.001, as well as survival to hospital discharge 
and early neurological response (see Supplemental Tables 2, 3, and 4 for full results of all 
regression models).
Figure 2 displays the results of the subgroup analyses. Mean MAP > 90 mmHg was found to 
be associated with good neurological outcome among all subgroups. The association 
between mean MAP > 90 mmHg and good neurological outcome was found to be stronger 
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among subjects with a previous diagnosis of hypertension compared to those without 
hypertension, relative risk 4.95 (95% CI 2.18 – 11.26) vs. 1.28 (95% CI 1.13 – 1.46) 
respectively.
We did not find evidence that the association between mean MAP > 90 mmHg and good 
neurological outcome differed as vasopressor dose increased (Supplemental Table 5). Figure 
3 displays the proportion of good neurological outcome across ascending ranges of mean 
MAP. Entering mean MAP as a categorical variable into the original model we found a dose-
response increase in the probability of good neurological outcome among all mean MAP 
ranges above 90 mmHg compared to the reference range of post-resuscitation MAP 70–80 
mmHg (Supplemental Table 6). Mean MAP > 110 mmHg had the strongest association with 
good neurological outcome at hospital discharge, [adjusted relative risk 2.97 (95% CI 1.86 – 
4.76), p = <0.001]. We also found for every additional hourly blood pressure measurement 
with MAP > 90 mmHg there was a 15% increase in the probability of good neurological 
outcome [adjusted relative risk 1.15 (95% CI 1.11–1.18), p < 0.001] (Supplemental Table 7). 
Among patients who survived to hospital discharge, 67% had good neurological outcome at 
hospital discharge. Mean MAP > 90 mmHg remained an independent predictor of good 
neurological outcome among survivors to hospital discharge, relative risk 1.36 (95% CI 
1.08–1.72) (Supplemental Table 8).
Discussion
In this multicenter prospectively compiled cohort, we tested the association between 
elevated MAP after resuscitation from cardiac arrest and neurological outcome. By 
excluding patients with persistent hypotension we were able to test if the association 
between arterial blood pressure and neurological outcome was driven by exposure to higher 
arterial blood pressure as opposed to exposure to arterial hypotension. In this cohort 59% of 
patients had a mean MAP > 90 mmHg during the initial six hours after ROSC. Compared to 
a mean MAP 70–90 mmHg, a MAP > 90 mmHg was independently associated with good 
neurological outcome at hospital discharge. Our results suggest a dose-response association 
between duration of exposure to MAP > 90 mmHg and good neurological outcome, as well 
as higher MAPs and good neurological outcome, with post-resuscitation MAP > 110 mmHg 
having the strongest association. In addition, we found an elevated MAP to be associated 
with good early neurological response as well as survival to hospital discharge. Good early 
neurological response was associated with survival to hospital discharge, suggesting that 
neurological injury was a major factor for mortality. Thus, it is reasonable to infer that the 
association between post-resuscitation MAP and mortality is mediated by early neurological 
injury. In summary, in this prospective, multicenter cohort, we found that elevated MAP 
during the early period after ROSC is associated with good neurological outcome.
In subgroup analyses we found the relationship between mean MAP > 90 mmHg and good 
neurological outcome was similar regardless of location of arrest, initial rhythm, or 
administration of vasopressor agent. Of note we found the association between mean MAP > 
90 mmHg and good neurological outcome was stronger among subjects with a previous 
diagnosis of hypertension compared to among those without hypertension. The stronger 
association among subjects with a history of chronic hypertension may suggest an 
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underlying shift in the cerebral autoregulation curve resulting in these patients requiring a 
higher MAP to maintain adequate cerebral blood flow at baseline.(29, 30) Thus, patients 
with a history of hypertension may be more susceptible to additional brain injury when 
exposed to lower arterial blood pressure. These findings suggest that the optimal MAP may 
be patient dependent and that some patients may benefit from MAPs higher than the current 
recommendation of maintaining MAP > 65 mmHg.(7)
During the early post-ROSC period, shifts in arterial blood pressure could potentially put 
patients at risk for additional brain injury, and thus maintenance of an elevated MAP during 
this time may improve cerebral blood flow and confer neuroprotection. This hypothesis is 
supported by animal models, in which an induced hypertensive surge attenuates brain injury 
and improves outcomes.(31–34) Our group previously performed a single center prospective 
cohort study examining the association between elevated MAP and neurological outcome.(9) 
We found that a MAP less than 70 mmHg is associated with poor neurological outcome. 
While we did not observe an association with increasing MAPs above 90 mmHg and 
improved neurological outcome, this study was limited by a single center design, inclusion 
of only 12 patients with a MAP > 100 mmHg, and inconsistent use of targeted temperature 
management.
This current investigation has several advantages over previous studies that advance this area 
of investigation. First we prospectively collected MAP measurements and vasopressor 
utilization over the initial six hours after ROSC. Additionally, we obtained protocol directed 
assessments of neurological disability in real time, as opposed to abstracting this information 
through chart review. Furthermore, all subjects received consistent guideline-driven post-
cardiac arrest care including targeted temperature management. Second, this study 
represented a larger multicenter population, with the majority of patients exhibiting a post-
resuscitation MAP greater than 90 mmHg. In addition, we excluded patients with persistent 
post-resuscitation hypotension from our analyses to ensure our results were driven by 
elevated blood pressure as opposed to exposure to hypotension.
We acknowledge that this study has important limitations to consider. First, this was an 
observational study and thus we can only report association rather than infer causation. It is 
possible that post-resuscitation MAP > 90 mmHg reflects a patient population that is less ill 
in general and therefore has a higher likelihood to have good neurological outcome. 
However, we did not observe any significant differences in the post-resuscitation SOFA 
score, alveolar plateau pressure, or incidence of post-resuscitation percutaneous coronary 
intervention or hypoxia between the two groups, suggesting this was not the case. Compared 
to patients with a mean MAP > 90 mmHg, we found patients with a mean MAP 70–90 
mmHg were less likely to have good early neurological response, as well as more likely to 
have withdraw of life sustaining therapy. However, we are unable to determine if lower MAP 
causes early neurological injury leading to withdraw of care, or if lower MAP is a marker for 
severity of illness influencing clinician decision to withdraw care. However, we found the 
association between mean MAP > 90 mmHg and good neurological outcome at hospital 
discharge remained statistically significant when limited to subjects who survived to hospital 
discharge, suggesting that the decision to withdraw life sustaining therapy did not confound 
our results. While we did observe patients with a mean MAP of 70–90 mmHg had a longer 
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duration of CPR compared to patients with a MAP > 90 mmHg, after adjusting all of our 
models for duration of CPR, mean MAP > 90 mmHg remained an independent predictor of 
good neurological outcome. Second, although we prospectively recorded MAP at least every 
hour, we did not require invasive blood pressure monitoring. However, the non-invasive 
blood pressure (cuff) measurement technique is accurate and ubiquitous in routine clinical 
practice. Thus our results are generalizable. Third, although all our clinicians aim to prevent 
exposure to hypotension as per current post-cardiac arrest guidelines,(7, 8) given there is 
equipoise as to the optimal target MAP, our protocol did not involve a standardized blood 
pressure target. Thus, blood pressure goals varied between treating clinicians. Of note, 
among patients with a mean MAP > 90 mmHg who were on vasopressors, 25/59 (42%) had 
exposure to hypotension during the initial six hours after ROSC. Thus, among these 25 
patients it is possible that the higher MAPs were the result of a rebound in blood pressure 
while attempting to treat hypotension. However, it is likely that the remaining patients with 
higher MAPs who received vasopressors did so as a result of clinicians specifically targeting 
higher MAPs. Fourth, although we used multivariable Poisson regression analyses to adjust 
for cardiac arrest characteristics known to predict poor outcomes, there exists the potential 
of unmeasured confounders. Fifth, although we prospectively recorded administration of 
vasopressor infusion, and quantified the administered dose using the cardiovascular 
component of the SOFA score we did not collect data on number of vasopressor agents 
administered.
Conclusion
Mean arterial blood pressure greater than 90 mmHg during the initial six hours after ROSC 
is associated with good neurological outcome at hospital discharge. This association was 
strongest among patients with a history of chronic hypertension, suggesting the association 
between arterial blood pressure and neurological outcome may be patient dependent. Further 
investigation is warranted to determine if interventions targeting an elevated arterial blood 
pressure would improve neurologic outcome after cardiac arrest and which patient 
populations may benefit.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1: 
Modified Rankin Scale at hospital discharge stratified by mean MAP (mean arterial blood 
pressure) 70–90 mmHg (gray columns) and mean MAP > 90 mmHg (black columns).
mRS: 0, no symptoms; 1, no significant disability; 2, slight disability; 3, moderate disability; 
4, moderate severe disability; 5, severe disability; 6, death
Roberts et al. Page 11
Crit Care Med. Author manuscript; available in PMC 2020 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 2: 
Subgroup analyses: adjusted relative risks (squares) with 95% confidence intervals 
(horizontal lines) for the association between mean MAP (mean arterial blood pressure) > 90 
mmHg (compared to 70–90 mmHg) and good neurological outcome (defined as a modified 
Rankin Scale (mRS) ≤ 3). We found mean MAP > 90 mmHg to be an independent predictor 
of good neurological outcome among all subgroups.
*Relative risks were calculated using multivariable Poisson regression analysis (using a log 
link) adjusting for age, initial cardiac rhythm, and duration of cardiopulmonary resuscitation 
[initial cardiac rhythm was excluded from pulseless electrical activity (PEA)/asystole and 
ventricular tachycardia/ventricular fibrillation (VT/VF) analyses]. HTN, hypertension; 
IHCA, in-hospital cardiac arrest; OHCA, out-of-hospital cardiac arrest.
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Figure 3: 
Good neurologic function at hospital discharge (defined as a modified Rankin Scale (mRS) 
≤ 3) in relation to mean MAP (mean arterial pressure) during the initial six hours after return 
of spontaneous circulation.
MAP; mean arterial blood pressure; ROSC, return of spontaneous circulation
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Table 1:
Baseline data for all subjects at the time of cardiac arrest.
Variable
All Subjects
n = 269
Mean MAP*
70–90 mmHg
n = 110
Mean MAP
> 90 mmHg
n = 159
p - value
Age [years (SD)] 58 (15) 61 (17) 57 (13) 0.037
Female [n (%)] 97 (36) 38 (35) 59 (37) 0.667
Pre-existing comorbidities [n (%)]
 Diabetes 66 (25) 25 (23) 41 (26) 0.567
 Known coronary artery disease 72 (27) 30 (27) 42 (26) 0.876
 Hypertension 178 (66) 71 (65) 107 (67) 0.639
 Malignancy 18 (7) 11 (10) 7 (4) 0.071
 Renal insufficiency 41 (15) 19 (17) 22 (14) 0.441
 Pulmonary disease 63 (23) 28 (25) 35 (22) 0.512
 Cerebral vascular disease 24 (9) 12 (11) 12 (8) 0.342
 Congestive heart failure 68 (25) 35 (32) 33 (21) 0.040
Charlson comorbidity score 1 (0–3) 1 (0–3) 1 (0–2) 0.078
Arrest location [n (%)]
 Out-of-hospital 209 (78) 78 (71) 131 (82)
 In-hospital 60 (22) 32 (29) 28 (18) 0.026
Initial arrest rhythm [n (%)]
 PEA/asystole 149 (55) 69 (63) 80 (50)
 VF/VT 99 (37) 36 (33) 63 (40) 0.075
 Unknown 21 (8) 5 (5) 16 (10)
CPR duration (min) 15 (7–23) 17 (8–28) 10 (6–20) 0.006
*
Mean MAP (mean arterial blood pressure) over the initial six hours after return of spontaneous circulation. CPR, cardiopulmonary resuscitation; 
IQR, interquartile range; PEA, pulseless electrical activity; SD, standard deviation; VF, ventricular fibrillation; VT ventricular tachycardia
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Table 2:
Adjusted relative risk for mean MAP (mean arterial blood pressure) > 90 mmHg (compared to reference 70–
90 mmHg) for the primary and secondary outcomes.
Outcome Relative Risk 95% CI p-value
Primary Outcome:
 Good Neurological Outcome* 2.46 2.09 – 2.88 <0.001
Secondary Outcomes:
 In-hospital mortality 1.90 1.64 – 2.20 <0.001
 Good early neurological response† 1.36 1.17 – 1.58 <0.001
*
Defined as modified Rankin Scale (mRS) ≥ 3 at hospital discharge;
†
Defined as a Full Outline of UnResponsiveness (FOUR) score > 6 at 72 hours after return of spontaneous circulation. CI, confidence interval. 
Results of the full models are displayed in the supplemental material.
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